We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

COVID-19 Vaccines Under Development Not Guaranteed to Work, Warns Merck CEO

By HospiMedica International staff writers
Posted on 16 Jul 2020
COVID-19 vaccines that are currently under development are not guaranteed to work and those claiming that a vaccine would be ready before the year-end are doing a “grave disservice to the public,” according to Kenneth Frazier, Chief Executive of Merck (Kenilworth, NJ, USA).

In an interview published on a Harvard Business School website, Frazier said that the potential COVID-19 vaccines may lack the qualities required for rapid deployment among a large population. “If you’re going to use a vaccine on billions of people, you better know what that vaccine does,” he said.

Image: COVID-19 Vaccines Under Development Not Guaranteed to Work, Warns Merck CEO (Photo courtesy of Merck)
Image: COVID-19 Vaccines Under Development Not Guaranteed to Work, Warns Merck CEO (Photo courtesy of Merck)

Frazier’s comments came soon after a US official stated that drugmakers partnering with the US government were on track to begin actively manufacturing a COVID-19 vaccine by summer end. The Trump administration has rolled out Operation Warp Speed Program with a target to produce 300 million vaccine doses by the end of 2021. Merck plans to study potential vaccine and therapy candidates for COVID-19 but has not yet begun clinical trials for its vaccine.

Frazier warned that some previous vaccines “not only didn’t confer protection, but actually helped the virus invade the cell, because it was incomplete in terms of its immunogenic properties. So we have to be very careful.”

Related Links:
Merck


Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Hospital Data Analytics Software
OR Companion
New
Fetal and Maternal Monitor
F9 Series

Latest COVID-19 News

Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles

World's First Inhalable COVID-19 Vaccine Approved in China

COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles